| Literature DB >> 30234080 |
Aleksandar Sovtic1,2, Predrag Minic1,2, Gordana Markovic-Sovtic1, Goran Z Trajkovic2,3.
Abstract
Introduction: Decreased respiratory muscle strength in patients with cystic fibrosis (CF) may cause progressive exercise intolerance during cardiopulmonary exercise testing (CPET), and may contribute to the development of chronic respiratory insufficiency. The aim of this study is to evaluate exercise tolerance during CPET of children and adults with clinically stable CF who exhibit different respiratory muscle strength.Entities:
Keywords: cystic fibrosis; exercise testing; respiratory muscle strength; spirometry; whole body plethysmography
Year: 2018 PMID: 30234080 PMCID: PMC6131603 DOI: 10.3389/fped.2018.00244
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Demographic data.
| Age (years) | 16.8 ± 6.5 | 17.7 ± 6.5 | 15.8 ± 6.5 | 12.3 ± 3.1 | 23.4 ± 4.1 |
| Exacerbation score (1/year) | 1.6 ± 0.7 | 1.4 ± 0.7 | 1.7 ± 0.7 | 1.5 ± 0.7 | 1.5 ± 0.7 |
| BMI | 18.4 ± 3.3 | 19.2 ± 3.4 | 17.6 ± 2.9 | 17.3 ± 3.3 | 20.3 ± 2.5 |
| FEV1 (%) | 76.5 ± 27.1 | 76.7 ± 28.3 | 76.4 ± 26.2 | 84.3 ± 25.8 | 65.1 ± 25.1 |
| FVC (%) | 83.0 ± 23.3 | 83.8 ± 24.9 | 82.2 ± 21.8 | 86.5 ± 23.4 | 77.8 ± 22.6 |
| RV/TLC (%) | 167.8 ± 53.3 | 166.3 ± 57.8 | 169.4 ± 48.7 | 158.1 ± 48.4 | 182, 0 ± 57.7 |
| VO2peak/kg | 33.2 ± 7.5 | 35.1 ± 7.8 | 31.2 ± 6.6 | 35.6 ± 6.7 | 29.8 ± 7, 3 |
| VO2peak/kg−0.67 | 115.3 ± 28.8 | 127.2 ± 27.5 | 102.2 ± 24.4 | 116.2 ± 27.3 | 113.9 ± 31.3 |
| VO2peak/kgalo | 4.2 ± 0.3 | 4.3 ± 0.3 | 4.1 ± 0.3 | 4.4 ± 0.3 | 4.2 ± 0.2 |
| Wmax (%) | 85.1 ± 17.6 | 83.2 ± 19.4 | 87.2 ± 15.5 | 82.7 ± 16.1 | 88.5 ± 19.5 |
| Pimax (%) | 108.1 ± 34.6 | 102.1 ± 39.3 | 114.6 ± 27.7 | 112.1 ± 37.0 | 102.1 ± 30.3 |
| Pemax (%) | 104.3 ± 34.4 | 100.2 ± 33.6 | 108.8 ± 35.3 | 102.9 ± 32.9 | 106.4 ± 37.1 |
| VE/VCO2 Wmax | 32.4 ± 4.2 | 31.4 ± 4.3 | 33.5 ± 3.7 | 32.8 ± 3.8 | 31.9 ± 4.6 |
| BRI Wmax | 0.8 ± 0.3 | 0.9 ± 0.3 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.9 ± 0.3 |
| SpO2 rest (%) | 96.7 ± 2.0 | 96.9 ± 1.8 | 96.5 ± 2.2 | 96.9 ± 1.9 | 96.3 ± 2.2 |
| SpO2 Wmax (%) | 91.7 ± 5.4 | 91.7 ± 4.9 | 91.7 ± 5.9 | 93.1 ± 4.4 | 89.7 ± 6.1 |
RV/TLC, residual volume/total lung capacity; Wmax, maximal load; VO2peak/kg, maximal oxygen consumption/kg; BRI, breathing reserve index; Pimax, maximal inspiratory pressure; Pemax, maximal expiratory pressure; VE/VCO2, ventilatory equivalent for carbon dioxide.
p < 0.05,
p < 0.01.
Exercise testing and respiratory muscle strength.
| Pemax (% pred) | ≤80% | 15 | 72.7 ± 17.2 | 27.9 ± 6.5 | 98.9 ± 36.6 | 4.1 ± 0.4 | 7.3 ± 1.9 |
| 81–100% | 22 | 83.1 ± 16.5 | 34.6 ± 6.9 | 121.8 ± 25.7 | 4.3 ± 0.3 | 6.6 ± 1.5 | |
| >100 | 32 | 92.3 ± 15.3 | 34.8 ± 7.4 | 118.4 ± 24.4 | 4.2 ± 0.3 | 6.5 ± 1.5 | |
| Total | 69 | 85.1 ± 17.6 | 33.3 ± 7.5 | 115.3 ± 28.8 | 4.2 ± 0.3 | 6.7 ± 1.6 | |
| Pimax (% pred) | ≤80% | 14 | 75.4 ± 20.9 | 32.8 ± 9.48 | 117.2 ± 32.3 | 4.3 ± 0.3 | 7.5 ± 1.9 |
| 81–100% | 15 | 88.2 ± 16.6 | 32.1 ± 9.4 | 120.4 ± 34.0 | 4.3 ± 0.3 | 6.8 ± 1.4 | |
| >100 | 40 | 87.3 ± 15.9 | 33.8 ± 5.9 | 112.7 ± 25.7 | 4.2 ± 0.3 | 6.4 ± 1.5 | |
| Total | 69 | 85.1 ± 17.6 | 33.3 ± 7.5 | 115.3 ± 28.8 | 4.2 ± 0.3 | 6.7 ± 1.6 |
Wmax, maximal load; VO2peak/kg, maximal oxygen consumption/kg; VO2peak, expressed relative to BM raised by the exponent of 0.67 (VO2peak/kg0.67); log-linear adjustment of VO2peak (VO2peak/kgalo); Pimax, maximal inspiratory pressure; Pemax, maximal expiratory pressure.
p < 0.05.
p < 0.01.
Linear regression with Wmax as a dependent variable.
| Pimax | 11.9 | 6.1 | 0.05 | −4.5 | 6.40 | 0.49 |
| Pemax | 24.9 | 5.5 | <0.001 | 20.6 | 6.75 | 0.003 |
| FEV1 (%) | 0.30 | 0.07 | <0.001 | 0.14 | 0.22 | 0.26 |
| RV/TLC (%) | −0.15 | 0.04 | <0.001 | −0.04 | 0.06 | 0.48 |
RV/TLC, residual volume/total lung capacity; Pi.
Figure 1Association between Pemax and Wmax.